188
Views
19
CrossRef citations to date
0
Altmetric
Original Research

Initiating/maintaining long-acting injectable antipsychotics in schizophrenia/schizoaffective or bipolar disorder – expert consensus survey part 2

, , , , , , & show all
Pages 1475-1492 | Published online: 08 Jun 2018

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (5)

John FP Bridges, Joseph F Goldberg, Heather M Fitzgerald, Sanjeda R Chumki, Kathleen Beusterien, Oliver Will & Leslie Citrome. (2023) Prioritizing Treatment Goals of People Diagnosed with Bipolar I Disorder in the US: Best–Worst Scaling Results. Patient Preference and Adherence 17, pages 2545-2555.
Read now
Ruth Milz, Carmela Benson, Karl Knight, Jose Antunes, Dean Najarian, Paola-Maria Lopez Rengel, Steven Wang, Ute Richarz, Srihari Gopal & John M Kane. (2023) The Effect of Longer Dosing Intervals for Long-Acting Injectable Antipsychotics on Outcomes in Schizophrenia. Neuropsychiatric Disease and Treatment 19, pages 531-545.
Read now
Mikkel Højlund & Christoph U. Correll. (2023) Switching to long-acting injectable antipsychotics: pharmacological considerations and practical approaches. Expert Opinion on Pharmacotherapy 24:13, pages 1463-1489.
Read now
Peter M. Haddad & Christoph U. Correll. (2023) Long-acting antipsychotics in the treatment of schizophrenia: opportunities and challenges. Expert Opinion on Pharmacotherapy 24:4, pages 473-493.
Read now
Renato de Filippis, Pasquale De Fazio, Raffaele Gaetano, Luca Steardo, Clemente Cedro, Antonio Bruno, Rocco Antonio Zoccali & Maria Rosaria Anna Muscatello. (2021) Current and emerging long-acting antipsychotics for the treatment of schizophrenia. Expert Opinion on Drug Safety 20:7, pages 771-790.
Read now

Articles from other publishers (14)

Blake R. EricksonJarrod EhrieSamuel MurrayRyan J. DoughertyMilton L. WainbergLisa B. DixonMatthew L. Goldman. (2023) A Rapid Review of “Low-Threshold” Psychiatric Medication Prescribing: Considerations for Street Medicine and Beyond. Psychiatric Services 74:3, pages 282-291.
Crossref
Christoph U. Correll, Craig Chepke, Paul Gionfriddo, Joe Parks, Phyllis Foxworth, Anirban Basu, Teri S. Brister, Dawn Brown, Christopher Clarke & Youssef Hassoun. (2022) The post COVID-19 healthcare landscape and the use of long-acting injectable antipsychotics for individuals with schizophrenia and bipolar I disorder: the importance of an integrated collaborative-care approach. BMC Psychiatry 22:1.
Crossref
Roger W. Sommi, Bhaskar Rege, Angela Wehr, Sejal Faldu, Yangchun Du & Peter J. Weiden. (2020) Aripiprazole Lauroxil Dosing Regimens: Understanding Dosage Strengths and Injection Intervals. CNS Spectrums 27:3, pages 262-267.
Crossref
Lisa Lewis & Jill Rodgers. (2022) Development and Evaluation of a Web-Based Educational Toolkit on the Knowledge, Attitudes, and Practices of Psychiatric Prescribers Regarding Long-Acting Injectable Antipsychotics. Journal of the American Psychiatric Nurses Association 28:2, pages 117-127.
Crossref
Petru Ifteni, Paula-Simina Petric & Andreea Teodorescu. (2021) Rating Opportunity for Long-Acting Injectable Antipsychotic Initiation Index (ROLIN). Frontiers in Psychiatry 12.
Crossref
John M. Kane, Joseph P. McEvoy, Christoph U. Correll & Pierre-Michel Llorca. (2021) Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia. CNS Drugs 35:11, pages 1189-1205.
Crossref
Daniel Guinart, Heidi Taipale, Jose M Rubio, Antti Tanskanen, Christoph U Correll, Jari Tiihonen & John M Kane. (2021) Risk Factors, Incidence, and Outcomes of Neuroleptic Malignant Syndrome on Long-Acting Injectable vs Oral Antipsychotics in a Nationwide Schizophrenia Cohort. Schizophrenia Bulletin 47:6, pages 1621-1630.
Crossref
Lorenzo Tatini, Giulio D’Anna, Francesco Pietrini, Eugenia Calligaris, Andrea Ballerini & Valdo Ricca. (2021) Predictors of long-acting injectable antipsychotic treatment discontinuation in outpatients with schizophrenia: relevance of the Drug Attitude Inventory-10. International Clinical Psychopharmacology 36:4, pages 181-187.
Crossref
Amal Abdel‐Baki, Dominic Thibault, Sofia Medrano, Emmanuel Stip, Martin Ladouceur, Ramzan Tahir & Stephane Potvin. (2019) Long‐acting antipsychotic medication as first‐line treatment of first‐episode psychosis with comorbid substance use disorder. Early Intervention in Psychiatry 14:1, pages 69-79.
Crossref
Emmanuel Stip, Syed Javaid, Jonathan Bayard-Diotte, Karim Abdel Aziz & Danilo Arnone. (2020) Use of long acting antipsychotics and relationship to newly diagnosed bipolar disorder: a pragmatic longitudinal study based on a Canadian health registry. Therapeutic Advances in Psychopharmacology 10, pages 204512532095711.
Crossref
Robert Cowan, Joshua M. Cohen, Erik Rosenman & Ravi Iyer. (2019) Physician and patient preferences for dosing options in migraine prevention. The Journal of Headache and Pain 20:1.
Crossref
Luisa Peters, Amanda Krogmann, Laura von Hardenberg, Katja Bödeker, Viktor B. Nöhles & Christoph U. Correll. (2019) Long-Acting Injections in Schizophrenia: a 3-Year Update on Randomized Controlled Trials Published January 2016–March 2019. Current Psychiatry Reports 21:12.
Crossref
Libor Ustohal. (2019) Maintenance treatment of schizophrenia with long‑acting injectable antipsychotics - work with patients and their family members. Psychiatrie pro praxi 20:1, pages 12-16.
Crossref
Qian Cai, Charmi Patel, Edward Kim, Nancy Connolly, Ozgur Tunceli & Antoine C. El Khoury. (2019) Factors Associated with the Initiation of Long-Acting Injectable Paliperidone Palmitate Versus Aripiprazole Among Medicaid Patients with Schizophrenia: An Observational Study. Advances in Therapy 36:4, pages 858-869.
Crossref